NEUROMOLECULAR MEDICINE, published by HUMANA PRESS INC, is a prestigious peer-reviewed journal dedicated to advancing the fields of cellular and molecular neuroscience, molecular medicine, and neurology. With an ISSN of 1535-1084 and an E-ISSN of 1559-1174, the journal boasts a significant presence in academic research since its inception in 2002 and continues to publish cutting-edge studies through 2024. Ranked in the Q2 category for 2023 in various disciplines, including Neuroscience and Molecular Medicine, it holds impressive positions in Scopus rankings, including 41st out of 192 in Neuroscience and Neurology. Although not an open access journal, NEUROMOLECULAR MEDICINE remains invaluable for researchers, professionals, and students seeking to explore the intricate relationships between molecular mechanisms and neurological functions, thereby contributing to the scientific understanding of nervous system diseases and therapeutic innovations.

Molecular Pain, published by SAGE Publications Inc, is a leading open access journal dedicated to advancing the field of pain research and management. Since its establishment in 2005, the journal has provided a vital platform for researchers and professionals to share significant findings in anesthesiology and pain medicine, cellular and molecular neuroscience, and molecular medicine. With an impressive impact factor and a strong reputation as evidenced by its Q1 categorization in Anesthesiology and Pain Medicine, this journal ranks among the top resources in its field, positioned in the 79th percentile for Pain Medicine and holding a noteworthy presence within the academic community. The journal’s commitment to disseminating high-quality research underlines its relevance and importance, making it a crucial reference for students, scientists, and clinicians alike. By promoting a deeper understanding of pain mechanisms, Molecular Pain fosters interdisciplinary collaboration and encourages innovative therapeutic approaches, ultimately enhancing patient care and outcomes.

ACTA PHARMACOLOGICA SINICA is a premier journal in the field of pharmacology, published by the esteemed Nature Publishing Group. With a strong history since its inception in 1980, this journal is recognized for its impactful contributions to the fields of medicine and pharmacology, consistently securing a Q1 ranking in multiple relevant categories, including Pharmacology (Medical). Drawing on a robust international readership, it ranks impressively at #8 out of 272 in the specialty of Medical Pharmacology, placing it in the top 97th percentile according to Scopus data. Although currently not an open-access publication, ACTA PHARMACOLOGICA SINICA remains a vital resource for researchers, professionals, and students seeking to advance their understanding of pharmacological sciences. Its commitment to disseminating high-quality research underscores its significance in fostering innovation and exploration in the medical landscape.

Welcome to the Korean Journal of Physiology & Pharmacology, a pivotal academic platform dedicated to advancing the disciplines of physiology and pharmacology. Published by the esteemed Korean Journal of Physiology & Pharmacology, this journal has been disseminating valuable research findings since its inception in 1997 and continues to be a critical resource for researchers, professionals, and students in South Korea and beyond. With an ISSN of 1226-4512 and E-ISSN of 2093-3827, it offers insights into various aspects of drug action and physiological mechanisms. Although this journal currently does not subscribe to Open Access, it plays a vital role in bridging the gap between experimental and clinical studies, receiving commendations for its quality. In the 2023 Scopus rankings, it is notably positioned in the Q3 quartile for Pharmacology and Q4 for Physiology, reflecting its commitment to excellence. As the journal converges towards its comprehensive coverage in 2024, it remains a cornerstone for those looking to engage deeply with critical developments in these fields.

MEDICINAL RESEARCH REVIEWS, published by Wiley, is a leading journal in the fields of Drug Discovery, Molecular Medicine, and Pharmacology. With an impressive impact factor and esteemed standing in its category quartiles (Q1 in all three fields), this journal serves as a vital platform for the dissemination of cutting-edge research and reviews that drive innovation in therapeutic development and molecular health sciences. Since its inception in 1981, MEDICINAL RESEARCH REVIEWS has garnered a robust readership within the scientific community, underscored by its high rankings in Scopus – where it ranks #3 in Pharmacology and #2 in Drug Discovery, placing it within the top echelons of academic influence. Researchers, professionals, and students alike benefit from its rich content and comprehensive approaches to tackling complex medicinal challenges, making it an essential resource for those invested in advancing the frontiers of biomedical research.

BMC NEUROSCIENCE is a prominent open access journal dedicated to the dissemination of high-quality research within the dynamic and rapidly evolving field of neuroscience. Published by BMC, a well-respected leader in open access publishing, this journal facilitates the free exchange of knowledge since its inception in 2000. With the ISSN 1471-2202, BMC NEUROSCIENCE aims to address the diverse interests of the neuroscience community by covering a broad spectrum of topics, ranging from cellular and molecular neuroscience to general neurological studies, thus appealing to researchers, professionals, and students alike. Although it currently holds a Q4 ranking in Cellular and Molecular Neuroscience and a Q3 rank in miscellaneous Neuroscience categories, its commitment to advancing the understanding of brain function and disorders remains steadfast. The journal features a user-friendly Open Access model, ensuring that critical research findings are readily accessible to everyone, fostering collaboration and innovation in the field. As the journal continues to evolve towards its convergence years of 2024, it aspires to enhance its impact and global reach, making it a valuable resource for anyone interested in advancing neuroscience research.

NEUROIMMUNOMODULATION is a well-respected journal published by KARGER that focuses on the intricate interactions of the nervous and immune systems. With its ISSN 1021-7401 and E-ISSN 1423-0216, it serves as a vital resource for researchers and professionals interested in neuroimmunology and related fields. The journal has been committed to disseminating high-quality research from its inception in 1994 and continues to thrive, with its scope converged until 2024. Notably, it holds a Q3 ranking in 2023 across diverse categories such as Endocrine and Autonomic Systems, Endocrinology, Immunology, and Neurology, reflecting its significance in the scientific community. Although the journal is not open access, it remains an essential publication for advancing knowledge and fostering collaboration among scholars, making it a noteworthy source of cutting-edge findings in the complex interplay between neural and immune processes.

EXPERIMENTAL NEUROLOGY is a premier academic journal published by Academic Press Inc, Elsevier Science, focusing on advancements in the fields of Developmental Neuroscience and Neurology. With an impressive Impact Factor and ranked in the Q1 quartile of both categories—positioning it among the top-tier journals—this publication has established itself as a vital resource for researchers, clinicians, and students alike. Since its inception in 1959, it has fostered the dissemination of cutting-edge research and innovative approaches to understanding neurological function and related disorders. While EXPERIMENTAL NEUROLOGY currently operates under a subscription access model, its rich archives and ongoing contributions to the field continue to inspire and inform the next generation of neurobiologists. The journal also boasts a high ranking in Scopus, placing fourth in Developmental Neuroscience and twentieth in Neurology, indicating its robust influence and scholarly significance. For those committed to advancing knowledge in these critical areas, EXPERIMENTAL NEUROLOGY is an indispensable platform for inquiry and discovery.

NEUROSCIENTIST is a leading journal in the field of clinical neurology and neuroscience, published by SAGE Publications Inc. With an impressive impact factor reflected in its Q1 quartile ranking in both clinical neurology and miscellaneous neuroscience as of 2023, this journal positions itself as a crucial platform for the latest research and advancements in the neural sciences. Spanning from 1995 to 2024, NEUROSCIENTIST features a range of high-quality, peer-reviewed articles that cater to researchers, practitioners, and students alike. Although it does not offer Open Access options, the journal remains a vital resource owing to its Scopus rankings, situating it within the top percentile of its categories: ranked #28 out of 400 in clinical neurology and #15 out of 113 in general neuroscience. The journal's commitment to disseminating significant findings underlines its importance in fostering advancements in neurological understanding and treatment.

MOLECULAR PHARMACOLOGY, published by the American Society for Pharmacology and Experimental Therapeutics, is an influential peer-reviewed journal dedicated to advancing the field of pharmacology through comprehensive research on molecular mechanisms of drug action. With an impressive historic convergence from 1965 to 2024, this journal plays a pivotal role in disseminating high-quality research, showcasing significant findings that impact both clinical and experimental pharmacology. Notably, it holds a distinguished Q1 ranking in Pharmacology and a Q2 ranking in Molecular Medicine as of 2023, reflecting its prominence in the academic community. Researchers and practitioners engaged in pharmacological studies will benefit from the journal’s focus on new therapeutic strategies, drug development, and the molecular basis of drug action. While MOLECULAR PHARMACOLOGY is not an open-access journal, it offers a wealth of knowledge behind a subscription model, ensuring that contributors and readers maintain a high standard of academic rigor. Address all inquiries to the editorial office located at 9650 Rockville Pike, Bethesda, MD 20814-3995, United States.